CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis

被引:21
作者
Klocke, Katrin [1 ]
Holmdahl, Rikard [1 ]
Wing, Kajsa [1 ]
机构
[1] Karolinska Inst, Div Med Inflammat Res, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
arthritis; autoimmunity; cytotoxic T-lymphocyte antigen 4; regulatory T cell; tolerance; COLLAGEN-INDUCED ARTHRITIS; II COLLAGEN; RHEUMATOID-ARTHRITIS; IGG ANTIBODIES; TNF-ALPHA; TOLERANCE; MICE; DISEASE; PATHOGENESIS; INDUCTION;
D O I
10.1111/imm.12754
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) -mediated regulation of already tolerized autoreactive T cells is critical for understanding autoimmune responses. Although defects in CTLA-4 contribute to abnormal FOXP3(+) regulatory T (Treg) cell function in rheumatoid arthritis, its role in autoreactive T cells remains elusive. We studied immunity towards the dominant collagen type II (CII) T-cell epitope in collagen-induced arthritis both in the heterologous setting and in the autologous setting where CII is mutated at position E266D in mouse cartilage. CTLA-4 regulated all stages of arthritis, including the chronic phase, and affected the priming of autologous but not heterologous CII-reactive T cells. CTLA-4 expression by both conventional T (Tconv) cells and Treg cells was required but while Tconv cell expression was needed to control the priming of naive autoreactive T cells, CTLA-4 on Treg cells prevented the inflammatory tissue attack. This identifies a cell-type-specific time window when CTLA-4-mediated tolerance is most powerful, which has important implications for clinical therapy with immune modulatory drugs.
引用
收藏
页码:125 / 137
页数:13
相关论文
共 50 条
[1]   CTLA-4 directly inhibits osteoclast formation [J].
Axmann, R. ;
Herman, S. ;
Zaiss, M. ;
Franz, S. ;
Polzer, K. ;
Zwerina, J. ;
Herrmann, M. ;
Smolen, J. ;
Schett, G. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1603-1609
[2]   Genetic control of tolerance to type II collagen and development of arthritis in an autologous collagen-induced arthritis model [J].
Bäcklund, J ;
Nandakumar, KS ;
Bockermann, R ;
Mori, L ;
Holmdahl, R .
JOURNAL OF IMMUNOLOGY, 2003, 171 (07) :3493-3499
[3]  
Bäcklund J, 2002, EUR J IMMUNOL, V32, P3776, DOI 10.1002/1521-4141(200212)32:12<3776::AID-IMMU3776>3.0.CO
[4]  
2-A
[5]   T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway [J].
Bozec, Aline ;
Zaiss, Mario M. ;
Kagwiria, Rosebeth ;
Voll, Reinhard ;
Rauh, Manfred ;
Chen, Zhu ;
Mueller-Schmucker, Sandra ;
Kroczek, Richard A. ;
Heinzerling, Lucie ;
Moser, Muriel ;
Mellor, Andrew L. ;
David, Jean-Pierre ;
Schett, Georg .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (235)
[6]  
CLAGUE RB, 1994, BRIT J RHEUMATOL, V33, P336
[7]   Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans [J].
Corse, Emily ;
Allison, James P. .
JOURNAL OF IMMUNOLOGY, 2012, 189 (03) :1123-1127
[8]   Treg Cell Function in Rheumatoid Arthritis Is Compromised by CTLA-4 Promoter Methylation Resulting in a Failure to Activate the Indoleamine 2,3-Dioxygenase Pathway [J].
Cribbs, Adam P. ;
Kennedy, Alan ;
Penn, Henry ;
Read, Jordan E. ;
Amjadi, Parisa ;
Green, Patricia ;
Syed, Khaja ;
Manka, Szymon W. ;
Brennan, Fionula M. ;
Gregory, Bernard ;
Williams, Richard O. .
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) :2344-2354
[9]   Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy [J].
Ehrenstein, MR ;
Evans, JG ;
Singh, A ;
Moore, S ;
Warnes, G ;
Isenberg, DA ;
Mauri, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (03) :277-285
[10]   Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis [J].
Flores-Borja, Fabian ;
Jury, Elizabeth C. ;
Mauri, Claudia ;
Ehrenstein, Michael R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (49) :19396-19401